News and Trends 31 Mar 2020 Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant The Japanese heavyweight Ono Pharmaceutical has recruited Numab Therapeutics for a second time to co-develop a multi-specific antibody cancer treatment in a deal worth up to €246M (CHF 260M). The announcement follows a two-year collaboration between Ono and Numab announced in March 2017. Under the new agreement, which includes upfront and milestone payments, Ono has […] March 31, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […] March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email